
Ligand Pharmaceuticals Incorporated: updates and filings
Price
$288.67
November 20, 2026Market cap $5.8B
What Ploutos Investor adds for Ligand Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 3, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Sep 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 22, 2026Regulation FD disclosureForm8-K
- Sep 2, 2026Financial statements and exhibits (amendment)Form8-K/A
- Aug 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 22, 2026Shares registered for employeesFormS-8
- Jul 14, 2026Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosureForm8-K
- Jun 25, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, other material eventsForm8-K
- Jun 22, 2026Material agreement entered, other material eventsForm8-K
- Jun 9, 2026Officer or director change, shareholder voteForm8-K
- May 18, 2026Additional annual meeting materialFormDEFA14A
- May 18, 2026Material agreement enteredForm8-K
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 1, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Material agreement endedForm8-K
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 3, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 30, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Sep 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 2, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 22, 2026 | S-8 | Shares registered for employees | Document |
| Jul 14, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosure | Document |
| Jun 25, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, other material events | Document |
| Jun 22, 2026 | 8-K | Material agreement entered, other material events | Document |
| Jun 9, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 18, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 18, 2026 | 8-K | Material agreement entered | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | 8-K | Material agreement ended | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Sep 13, 1994: every report, 8-K, meeting and letter. Of its other filings (1,221 in all), the newest.
The full analysis
What do Ligand Pharmaceuticals's filings show?
The filings are where every one of Ligand Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.